is the biotech company we are supporting. They will lead a multipronged approach to repurposing FDA-approved drugs and other readily available compounds for treating CHOPS syndrome.
Unravel applies rapid prototyping concepts from engineering to seamlessly bridge target discovery with clinical efficacy to bring novel effective treatments to patients. It leverages its proprietary BioNAVTM platform combining drug discovery, patient stratification, and preclinical screening to identify key mechanisms and develop novel treatments for complex diseases impacting the whole body.
CHOPS Syndrome